NASDAQ · NTRA
Natera, Inc.
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
Loading market information…
NASDAQ · MYGN · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Myriad Genetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Myriad Genetics, Inc.’s forward annual dividend is $21.00 per share, paid monthly. The forward yield is 314.84% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Myriad Genetics, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.17. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Myriad Genetics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | -$0.03+40.0% vs estimate | $195.90M-7.47% vs estimate |
|---|
| Q4 2024 | Feb 24, 2025 | $0.030.0% vs estimate | $210.60M+0.12% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.06+215.79% vs estimate | $213.30M-0.12% vs estimate |
|---|
THE ANALYST VIEW
37 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $4.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
$50.34+$0.01 (+0.02%)
Qiagen N.V.’s quoted price sits in the upper half of its reported 52-week range, 12.94% below the high.
$114.84+$0.84 (+0.74%)
BillionToOne, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.66% below the high.
$52.17+$1.86 (+3.7%)
Veracyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.35% below the high.
$17.93-$0.06 (-0.33%)
NeoGenomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.02% below the high.
$15.93-$0.08 (-0.47%)
Personalis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
$21.68+$0.16 (+0.74%)
Fulgent Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.15% below the high.
